391 related articles for article (PubMed ID: 30338425)
1. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
Yan M; Bomeisl P; Gilmore H; Harbhajanka A
Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
[TBL] [Abstract][Full Text] [Related]
3. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
[TBL] [Abstract][Full Text] [Related]
5. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
7. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
8. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
[TBL] [Abstract][Full Text] [Related]
9. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
10. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
11. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Liu Y; West R; Weber JD; Colditz GA
Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
14. Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.
Tumedei MM; Silvestrini R; Ravaioli S; Massa I; Maltoni R; Rocca A; Folli S; Buggi F; Curcio A; Serra L; Puccetti M; Amadori D; Bravaccini S
Int J Biol Markers; 2015 Nov; 30(4):e425-8. PubMed ID: 26165687
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
16. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
[TBL] [Abstract][Full Text] [Related]
18. Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.
Ravaioli S; Tumedei MM; Foca F; Maltoni R; Rocca A; Massa I; Pietri E; Bravaccini S
Int J Exp Pathol; 2017 Oct; 98(5):289-295. PubMed ID: 29193395
[TBL] [Abstract][Full Text] [Related]
19. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.
Kurbel S
Tumour Biol; 2013 Feb; 34(1):1-7. PubMed ID: 23208673
[TBL] [Abstract][Full Text] [Related]
20. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
